Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director | May 12, 2026 | May 14, 2026 |
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | September 02, 2026 | September 04, 2026 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Chief Financial Officer | June 15, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,116 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Grant · Acquired 62,800 · Balance 63,116 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 94,200 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 94,200 · Balance 94,200 F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
BioXcel Therapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,335 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 35 · Balance 26,335 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 212 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 35 · Balance 212 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 01:54 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 7,175 | $0.55 | $3,946.25 |
DisclosureSEC source: 0001104659-24-106061 · tm2425607-2_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,279 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5515. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Oct 4, 2024 01:54 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantCommon Stock | 21,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-106061 · tm2425607-2_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,454 F1 · price: The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 356 | $0.69 | $245.60 |
DisclosureSEC source: 0001104659-24-100749 · tm2424255-3_4seq1.xml · nonDerivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,204 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100749 · tm2424255-3_4seq1.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100749 · tm2424255-3_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100749 · tm2424255-3_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100749 · tm2424255-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 22, 2024 Filed Apr 1, 2025 22:07 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 1,875 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-25-030685 · tm2511097-5_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2034-07-22 F2 · shares: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock. F4 · derivative.exercise_date: The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| July 22, 2024 Filed Apr 1, 2025 22:07 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-030685 · tm2511097-5_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 625 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock. F3 · derivative.exercise_date: The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date. F3 · derivative.expiration_date: The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-24-079563 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 372 | $1.26 | $469.54 |
DisclosureSEC source: 0001104659-24-073002 · tm2417544-5_4seq1.xml · nonDerivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,476 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073002 · tm2417544-5_4seq1.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,188 Underlying: Common Stock · 562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-073002 · tm2417544-5_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073002 · tm2417544-5_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,648 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-073002 · tm2417544-5_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 23:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 1,069 | $2.64 | $2,816.82 |
DisclosureSEC source: 0001104659-24-044860 · tm2411220-4_4seq1.xml · nonDerivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,765 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.62 to $2.665. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-044860 · tm2411220-4_4seq1.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-044860 · tm2411220-4_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2024 Filed Apr 8, 2024 23:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-044860 · tm2411220-4_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,169 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2024 Filed Apr 8, 2024 23:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-044860 · tm2411220-4_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:23 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 70,311 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-23-100086 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,311 Underlying: Common Stock · 70,311 shares Expires 2033-12-28 F1 · derivative.exercise_price: This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:52 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-126921 · tm2333119-2_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:52 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-126921 · tm2333119-2_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:49 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-101640 · tm2326350-5_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,211 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:49 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-101640 · tm2326350-5_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:42 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072397 · tm2319006-3_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,732 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:42 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-072397 · tm2319006-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 15, 2023 Filed May 17, 2023 00:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 5,000 | $27.17 | $135,863.50 |
DisclosureSEC source: 0001104659-23-061538 · tm2316022-2_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $26.84 to $27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061538 · tm2316022-2_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023. F4 · derivative.expiration_date: On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-061538 · tm2316022-2_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 04, 2023 Filed May 5, 2023 23:35 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001437749-23-012870 · rdgdoc.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001104659-23-033408 · tm239796-6_4seq1.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-03-15 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033408 · tm239796-6_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 2,084 | $19.50 | $40,638.00 |
DisclosureSEC source: 0001104659-23-033408 · tm239796-6_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033408 · tm239796-6_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 Underlying: Common Stock · 2,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-033408 · tm239796-6_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 23:16 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 72,156 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-22-036873 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,156 Underlying: Common Stock · 72,156 shares Expires 2032-07-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested. Read SEC document |
| May 14, 2022 Filed May 17, 2022 19:40 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-061919 · tm2215808-2_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| May 13, 2022 Filed May 16, 2022 22:20 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001437749-22-012710 · rdgdoc.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:16 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 33,350 | $0.00 Strike: $15.31 | $0.00 |
DisclosureSEC source: 0001104659-22-034488 · tm229449-2_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,350 Underlying: Common Stock · 33,350 shares Expires 2032-03-14 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:16 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 8,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-034488 · tm229449-2_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,337 Underlying: Common Stock · 8,337 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:02 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 18,351 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-21-046683 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,351 Underlying: Common Stock · 18,351 shares Expires 2031-09-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:16 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012672 · rdgdoc.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2020 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| March 25, 2021 Filed Mar 30, 2021 00:45 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $41.17 | $0.00 |
DisclosureSEC source: 0001104659-21-043484 · tm217124-12_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-03-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 25, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:15 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Option · Derivative | 3,750 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001104659-21-011542 · tm215213-1_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,148 Underlying: Common Stock · 3,750 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this stock option vested and became exercisable as to 21,093 shares on October 1, 2018, and the remaining 62,805 shares have vested or will vest monthly over 36 months from October 2, 2018 through October 1, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:15 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 3,750 | $48.15 | $180,562.50 |
DisclosureSEC source: 0001104659-21-011542 · tm215213-1_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.73. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:15 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 3,750 | $5.55 | $20,812.50 |
DisclosureSEC source: 0001104659-21-011542 · tm215213-1_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:03 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022320 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $45.99 | $0.00 |
DisclosureSEC source: 0001104659-20-067056 · a4.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-05-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of May 26, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.